

REFERENCES

1. Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. *Br J Psychiatry* 2013;202(5):321-3.
2. Ajmal A, Joffe H, Nachtigall L. Psychotropic-induced hyperprolactinemia: a clinical review. *Psychosomatics* 2014;55(1):29-36.
3. Allaire B, Raghavan R, Brown D. Morbid obesity and use of second generation antipsychotics among adolescents in foster care: evidence from Medicaid. *Child Youth Serv Rev* 2016;67:27-31.
4. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. *J Clin Psychiatry* 2005;66:1468-1476.
5. Babu G, Desai G, Chandra P. Antipsychotics in pregnancy and lactation. *Indian J Psychiatry* 2015;57(Suppl 2): S303-S307.
6. Ban L, Gibson JE, West J, Fiaschi L, Oates MR, Tata LJ. Impact of socioeconomic deprivation on maternal perinatal mental illnesses presenting to UK general practice. *Br J Gen Pract* 2012;62:e671-8.
7. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker W. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. *Am J Psychiatry* 1994;151(6):945.
8. Bellet F, Beyens MN, Bernard N, Beghin D, Elefant E, Vial T. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. *Pharmacoepidemiol Drug Saf* 2015;24(4):368-80.
9. Bennedsen BE. Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. *Schizophr Res* 1998;33:1-26.
10. Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. *Br J Psychiatry* 1999;175:239-45.
11. Bennedsen BE, Mortensen PB, et al. Congenital malformations, stillbirths, and infant deaths among children of women with schizophrenia. *Arch Gen Psychiatry* 2001;58:674-9.
12. Bergink V, Bouvy P, Vervoort J, Koorengevel K, Steegers E, Kushner S. Prevention of postpartum psychosis and mania in women at high risk. *Am J Psychiatry* 2012;169(6):609-15.
13. Bhatia T, Franzos MA, Wood JA, Nimgaonkar VL, Deshpande SN. Gender and procreation among patients with schizophrenia. *Schizophr Res* 2004;68:387-394.
14. Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. *BMJ* 2012;345:e7085.

15. Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. *Arch Gen Psychiatry* 2012;96:715–21.
16. Brunner E, Falk D, Jones M, Dey D, Shatapathy C. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. *Br Med Council Pharmacol Toxicol* 2013;2-13;14:38.
17. Bundy H, Stahl D, MacCabe J. A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. *Acta Psychiatr Scand* 2011;123:98–106.
18. Cohen L, Viguera A, McInerney K, Freeman M, Sosinsky Al, Moustafa D, Marfurt S, Kwiatkowski M, Murphy S, Farrell A, Chitayat D, Hernandez-Diaz S. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. *Am J Psychiatry* 2016;173(3):263-270.
19. Convertino I, Sansone A, Marino A, Galiulo M, Mantarro S, Antionioli L, Fornai M, Binadizzi C, Tuccori M. Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. *Drug Saf* 2016;39:903-924.
20. Coppola D, Russo L, Kwarta R, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. *Drug Saf* 2007;30:247-264.
21. Coughlin C, Blackwell K, Bartley C, Hay M, Yonkers K, Bloch M. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. *Obstet Gynecol* 2015;125:1224–1235.
22. Cuomo A, Goracci A, Fagiolini A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. *J Affect Disord* 2017;228:229-237.
23. Daniels J, Forssen U, Hultman C, Cnattingius S, David A, Feychting M, Sparen P. Parental psychiatric disorders associated with autism spectrum disorders in the offspring. *Pediatrics* 2008;121:1357-1362.
24. Dev V, Krupp P. The side effects and safety of clozapine. *Rev Contempor Pharmacother* 1995;6:197-208.
25. Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A. Safety of haloperidol and penfluridol in pregnancy: a multicenter prospective controlled study. *J Clin Psychiatry* 2005;66:317-322.
26. Dickson R, Hogg L. Pregnancy of a patient treated with clozapine. *Psychiatr Serv* 1998;49(8):1081-1083.
27. Di Florio A, Forty L, Gordon-Smith K, Heron J, Jones L, Craddock N, Jones I. Perinatal episodes across the mood disorder spectrum. *JAMA Psychiatry* 2013;70:168-175.
28. Di Michele V, Ramenghi L, Sabatino G. Clozapine and lorazepam administration in pregnancy. *Eur Psychiatry* 1996;11(4):214.
29. Einarsson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. *J Psychiatr Pract* 2009;15:183–192.

30. Ellman L, Huttunen M, Lonnqvist J, Cannon T. The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on obstetric complications. *Schizophr Res* 2007;93:1-3 229-236.
31. Epstein R, Bobo W, Shelton R, Arbogast P, Morrow J, Wang W, Chandrasekar R, Cooper W. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. *Pharmacoepidemiol Drug Saf* 2013;22:794-801.
32. Ennis Z, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: a systematic review. *Basic Clin Pharmacol Toxicol* 2015;116(4):315.
33. Freeman M, Sosinsky A, Goetz-Mogollon L, Savella G, Moustafa D, Viguera A, Cohen L. Gestational weight gain and pre-pregnancy body mass index associated with second-generation antipsychotic drug use during pregnancy. *Psychosomatics* 2018;59(2):125-134.
34. Freeman M, Sosinsky A, Moustafa D, Viguera A, Cohen L. Supplement use by women during pregnancy: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. *Arch Womens Ment Health* 2016;19(3):437-441.
35. Frise C, Attwood B, Watkinson P, Mackillop L. Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. *Obstet Med* 2016;9(1):46-49.
36. Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. *Ther Adv Drug Saf* 2014;5(2):100-109.
37. Garayt C, Merieux C. Pregnancy outcome in women exposed to atypical antipsychotics *European Network of Teratology Information Service Conference, 2009.*
38. Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. *Prog Neuropsychopharmacol Biol Psychiatry* 2012;36(1):71-77.
39. Gentile S. Clinical utilisation of atypical antipsychotics in pregnancy and lactation. *Ann Pharmacother* 2004;38:1265-1271.
40. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. *Schizophr Bull* 2010;36(3):518-533.
41. Gentile S. (More than half the women with a history of psychosis have a psychiatric episode in the first year after childbirth. *Evidence Based Ment Health* 2005;8(2):33.
42. Gentile S. A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. *Expert Opin Drug Saf.* 2014;13(12):1733-42.
43. Gentile S, Fusco M. Neurodevelopmental outcomes in infants exposed in utero to antipsychotics: a systematic review of published data. *CNS Spectrums* 2017;22(3):273-281.
44. Gilbert H. About Helen - antipsychotic medication use during pregnancy. A case study. *Aust Nurs J*

2009;16(7):20.

45. Goh I, Bollano E, Einarson T, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. *J Obstet Gynaecol Can* 2006;28(8):680-689.
46. Goldstein D, Corbin L, Fung M. Olanzapine-exposed pregnancies and lactation: early experience. *J Clin Psychopharmacol* 2000;20(4):399-403.
47. Guerin A, Nisenbaym R, Rag J. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. *Diabetes Care* 2007;30:1920-1925.
48. Gupta N, Grover S. Safety of clozapine in 2 successive pregnancies. *Can J Psychiatry* 2004;49(12):863.
49. Guyon L, Auffret M, Coussemacq M, Bene J, Deruelle P, Gautier S. Alteration of the fetal heart rate pattern induced by the use of clozapine during pregnancy. *Therapie* 2015;70(3):301-303.
50. Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C,
51. Meister R, Schaefer C. Atypical antipsychotic drugs and pregnancy outcome: a prospective cohort study. *J Clin Psychopharmacol* 2013;33:453-462.
52. Haddad P, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. *Drugs* 2004;64(20):2291-2314.
53. Haukka J, Suvisaari J, Lonnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. *Am J Psychiatry* 2003;160:460-463.
54. Hizkiyahu R, Levy A, Sheiner E. Pregnancy outcome of patients with schizophrenia. *Am J Perinat* 2009;27(1):9-23.
55. Howard L. The separation of mothers and babies in the treatment of postpartum disorders in Britain 1900-1960. *Arch Womens Ment Health* 2000;3:1-5.
56. Howard L, Goss C, Leese M, Thornicroft G. Medical outcome of pregnancy in women with psychotic disorders and their infants in the first year after birth. *Br J Psychiatry* 2003;182:63-67.
57. Howard L, Kumar C, Leese M, Thornicroft G. The general fertility rate in women with psychotic disorders. *Am J Psychiatry* 2002;159:991-997.
58. Howard L, Goss G, Leese M, Appleby L, Thornicroft G. The psychosocial outcome of pregnancy in women with psychotic disorders. *Schizophr Res* 2004;71:49-60.
59. Howard LM, Thornicroft G, Salmon M, Appleby L. Predictors of parenting outcome in women with psychotic disorders discharged from mother and baby units. *Acta Psychiatr Scand* 2004;110:347-355.
60. Howard L, Seneviratne T. Management of women with psychosis during pregnancy. *Prog Neurology Psychiatry* 2008;12(2):9-12.

61. Howard L, Oram S, Galley H, Trevillion K, Feder G. Domestic violence and perinatal mental disorders: a systematic review and meta-analysis. *PLoS Med* 2013;10(5):e1001452.
62. Hunt N, Silverstone T. Does puerperal illness distinguish a subgroup of bipolar patients? *Journal of Affective Disorders* 1995;34:101-107.
63. Huybrechts K, Hernandez-Diaz S, Patorno E, Desai R, Mogun H, Dejene S, Cohen J, Panchaud A, Cohen L, Bateman B. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatry* 2016;73(9):938-946.
64. Igarashi M. Floppy infant syndrome. *Journal of Clinical Neuromuscular Disorders* 2004;6(2):69-90
65. Jablensky A, Morgan V, Zubrick S, Bower C, Yellachich L. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. *American Journal of Psychiatry* 2005;162:79-91.
66. Johnson K, LaPrairie J, Brennan P, Stowe Z, Newport D. Prenatal antipsychotic exposure and neuromotor performance during infancy. *Archives of General Psychiatry* 2012;69(8):787-794.
67. Jokiranta E, Brown A, Heinimaa M, Cheslack-Postava K, Partanen A, Sourander A. Parental psychiatric disorders and autism spectrum disorders. *Psychiatry Research* 2013;207(3):203-211.
68. Judd F, Komiti A, Sheehan P, Newman L, Castle D, Everall I. Adverse obstetric and neonatal outcomes for women with severe mental illness: to what extent can they be prevented? *Schizophr Res* 2014;157(1-3):305-309.
69. Kallen B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. *Pharmaceuticals (Basel)* 2013;6(10):1221-1286.
70. Karakula H, Szajer K, Rpila B, Grzywa A, Chuchra M. Clozapine and pregnancy-a case history. *Pharmacopsychiatry* 2004;37(6):303-304.
71. King-Hele S, Webb R, Mortensen P, Appleby L, Pickles A, Abel K. Risk of stillbirth and neonatal death linked with maternal mental illness: a national cohort study. *Archives of Disease in the Child Fetal Neonatal Edition* 2009;94(2):105-110.
72. Koga M. Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment. *Seishin Shinkeigaku Zasshi* 2003;105(4):473-488.
73. Koren G. Misrepresentation and miscommunication of teratogenic risk of drugs; analysis of three highly publicised international cases. *Reproductive Toxicology* 2001;15(1):1-3.
74. Koren G, Cohn T, Chitayat D, Kapur B, Remington G, Reid D, Zipursky R. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. *American Journal of Psychiatry* 2002;159(1):136-7.
75. Koren G. What adversely affects the unborn--psychotropic drugs or maternal morbidity? *Journal of Clinical*

Psychiatry 2015;76(7):e904-5.

76. Kulkarni J, McCauley-Elsom K, Marston N, Gilbert H, Gurvich C, de Castella A, Fitzgerald P. Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy. *Australian and New Zealand Journal of Psychiatry* 2008;42:38-44.
77. Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen T, Wang W, McCauley K, Fitzgerald P. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. *PLoS ONE*. 2014;9(5):e94788.
78. Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. *Expert Opinion on Pharmacotherapy* 2015;16(9): 1335-45.
79. Larsson H, Eaton W, Madsen K, Vestergard M, Olesen A, Agerbo E, Schendel D, Thorsen P, Mortensen P. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. *American Journal of Epidemiology* 2005;161:916-925.
80. Laursen TM, Munk-Olsen T. Reproductive patterns in psychotic patients. *Schizophrenia Research* 2010;121:234-240.
81. Lee HC, Lin HC. Maternal bipolar disorder increased low birth weight and preterm births: a nationwide population-based study. *Journal of Affective Disorders* 2012;121:100-105.
82. Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? *Schizophrenia Research* 2010;116:55-60.
83. Lobstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. *J Psychiatr Neurosci* 1997;22(3):192-196.
84. Lopez-Yarto M, Ruiz-Mirazo E, Holloway A, Taylor V, McDonald S. Do psychiatric medications, especially antidepressants, adversely impact maternal metabolic outcomes? *J Affect Disord* 2012;141:120-129.
85. McCauley-Elsom K, Kulkarni J. Managing psychosis in pregnancy. *Aust N Z J Psychiatry* 2007;41:289-292.
86. McCauley-Elsom K, Gurvich C, Elsom S, Kulkarni J. Antipsychotics in pregnancy. *J Psychiatric Ment Health Nurs* 2009;17(2):97-104.
87. McColl H, Dhillon M, Howard LM. A systematic review of the nutritional status of women of a childbearing age with severe mental illness. *Arch Womens Ment Health* 2013;16(1):39-46.
88. McEvoy J, Meyer J, Goff D, Nasrallah H, Davis S, Sullivan L, Meltzer H, Hsiao J, Scott Stroup T, Lieberman J. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res* 2005;80:19-32.
89. McGrath JJ, Hearle J, Jenner L, Plant K, Drummond A, Barkla JM. The fertility and fecundity of patients with

- psychoses. *Acta Psychiatrica Scand* 1999;99:441–446.
90. McKenna K, Einarson A, Levinson A, Gideon K. Significant changes in antipsychotic drug use during pregnancy. *Veterinary Human Toxicol* 2004;46(1):44–46.
91. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky R, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *J Clin Psychiatry* 2005;66(4): 444-449.
92. McNeil T, Kaij L, Malmquist-Larsson A. Women with nonorganic psychosis: pregnancy's effect on mental health during pregnancy. *Acta Psychiatr Scand* 1984;70:140-148.
93. MacCabe J, Martinsson L, Lichtenstein P, Nilsson E, Cnattingius S, Murray E, Hultman C. Adverse pregnancy outcomes in mothers with affective psychosis. *Bipolar Disord* 2007;9(3):305-309.
94. Macritchie K, Young A, McElhatton P. Birth outcome following therapeutic atypical antipsychotics exposure during pregnancy: an ongoing prospective study. Abstracts of the European Association of Poisons Centre and Clinical Toxicologists XXVI International Congress published in *Clinical Toxicology* 2006;44(4):401-586.
95. Margulis A, Kang E, Hammad T. Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort. *J Matern Child Health* 2014;18:1742-1752.
96. Matevosyan N. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. *Arch Gynecol Obstet* 2011;283(2):141–147.
97. Mehta T, Van Lieshout R. A review of the safety of clozapine during pregnancy and lactation. *Arch Women's Ment Health* 2017;20(1):1-9.
98. Mei-Dan E, Ray J, Vigod S. Perinatal outcomes among women with bipolar disorder: a population-based cohort study. *Am J Obstet Gynecol* 2015;212(3):367.e1-8.
99. Mendhekar D, Sharma J, Srivastava P, War L. Clozapine and pregnancy. *J Clin Psychiatry* 2003;64(7):850.
100. Mendhekar D. Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation. *J Neuropsychiatry Clin Neurosci* 2007;19(2):196-7.
101. Miller L. Comprehensive care of pregnant mentally ill women. *J Mental Health Administration* 1992;19:170–7.
102. Miller L, Finnerty M. Sexuality, pregnancy, and childrearing among women with schizophrenia spectrum disorders. *Psychiatric Serv* 1996;47:502-506.
103. Miller L, Finnerty M. Family planning knowledge, attitudes and practices in women with schizophrenic spectrum disorders. *J Psychosoc Obstet Gynaecol* 1998;19:210-217.
104. Molyneaux E, Poston L, Ashurst-Williams S, Howard L. Obesity and mental disorders during pregnancy

- and postpartum: a systematic review and meta-analysis. *Obstet Gynecol* 2014;123(4):857-67.
105. Montastruc F, Salvo F, Arnaud M, Bead B, Pariente A. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from Vigibase. *Drug Saf* 2016;39(7):689-96.
106. Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen R. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. *J Clin Psychiatry* 2004;65(11):1491-1498.
107. Morgan V, Croft M, Valuri G, Zubrick S, Bower C, McNeil T, Jablensky A. Intellectual disability and other neuropsychiatric outcomes in high-risk children of mothers with schizophrenia, bipolar disorder and unipolar major depression. *Br J Psychiatry* 2012;200(4):282-289.
108. Munk E, Norgaard B, Gislum M, Mortensen P, Sorensen H. Use of antipsychotic drugs during pregnancy and the risk of adverse birth outcomes: a population-based cohort study. *Schizophr Bull* 2005;31:233.
109. Newham J, Thomas S, MacRitchie K, McElhatton P, McAllister-Williams R. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. *Br J Psychiatry* 2008;192:333-7.
110. Newport D, Calamaras M, DeVane C, Donovan J, Beach A, Winn S, Knight B, Gibson B, Viguera A, Owens M, Nemeroff C, Stowe Z. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. *Am J Psychiatry* 2007;164:1214-20.
111. Nguyen T, Faulkner D, Frayne J, Allen S, Hauck Y, Rock D, Rampono J. Obstetric and neonatal outcomes of pregnant women with severe mental illness at a specialist antenatal clinic. *Medical J Australia* 2013;199(suppl): S26-29.
112. National Institute for Health and Care Excellence; >NICE Guidance>Conditions and diseases>Fertility, pregnancy and childbirth>postnatal care; nice.org.uk.
113. Nilsson E, Lichtenstein P, Cnattingius S, Murray R, Hultman C. Women with schizophrenia: pregnancy outcome and infant death among their offspring. *Schizophr Res* 2002;58(2-3):221-229.
114. Nilsson E, Hultman C, Cnattingius S, Olausson P, Bjork C, Lichtenstein P. Schizophrenia and offspring's risk for adverse pregnancy outcomes and infant death. *Br J Psychiatry* 2008;193(4):311-315.
115. Nulman I, Citron S, Todorow M, Uleryk E. Neurodevelopment of children exposed to antidepressant and antipsychotic medications during pregnancy. In: Preece P, Riley E, eds. *Alcohol, drugs and medication in pregnancy: the long-term outcome for the child* London, England: Mac Keith Press, 2011:56-84.
116. Odegard O. Fertility of psychiatric first admissions in Norway 1936-1975. *Acta Psychiatr Scand* 1980;62:212-20.
117. Panchaud A, Hernandez-Diaz S, Freeman M, Viguera A, MacDonald S, Sosinsky A, Cohen L. Use of

- atypical antipsychotics in pregnancy and maternal gestational diabetes. *J Psychiatric Res* 2017;95:84-90.
118. Park SW, Phuong VT, Lee CH, Lee JG, Seo MK, Cho HY, Fang ZH, Lee BJ, Kim YH. Effects of antipsychotic drugs on BDNF, GSK-3 β , and β -catenin expression in rats subjected to immobilization stress. *Neurosci Res* 2011;71(4):335-340.
119. Park Y, Huybrechts K, Cohen J, Bateman B, Desair R, Patorno E, Mogun H, Cohen L, Hernandez-Diaz S. Antipsychotic medication use among publicly insured pregnant women in the United States. *Psychiatric Serv* 2017;68(11):1112-1119.
120. Paulus W, Shloemp S, Sterzik K. Atypical antipsychotic agents in early pregnancy. *Reprod Toxicol* 2005;20:477.
121. Paulus W. Is the use of aripiprazole safe during first trimester of pregnancy? *Reprod Toxicol* 2013;37:87.
122. Peng M, Gao K, Dong Y, Ou J, Calabrese J, Wu R, Zhao J. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. *Psychopharmacol (Berlin)* 2013;228(4):577-584.
123. Petersen I, McCrea R, Osborn D, Evans S, Pinfold V, Cowen P, Gilbert R, Nazareth I. Discontinuation of antipsychotic medication in pregnancy: a cohort study. *Schizophr Res* 2014;159(1):218-225.
124. Petersen I, Sammon C, McCrea D, Evans S, Cowen P, Nazareth I. Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records. *Schizophr Res* 2016;176:349-356.
125. Pinkofsky H, Fitzgerald M, Reeves R. Psychotropic treatment during pregnancy [letter]. *Am J Psychiatry* 1997;154:718-719.
126. Power R, Kyaga S, Uher R, MacCabe J, Langstrom N, Landen M, McGuffin P, Lewis C, Lichtenstein P, Svensson A. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. *JAMA Psychiatry* 2013;70(1):22-30.
127. Public Health Agency of Canada. Congenital Anomalies in Canada 2013: A perinatal health surveillance report. Ottawa, 2013.
128. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. *J Clin Psychopharmacol* 2008;28:279-88.
129. Rifkin L, Lewis S, Jones P, Toone B, Murray R. Low birth weight and schizophrenia. *Br J Psychiatry* 1994;165:357-362.
130. Rojo L, Gaspar P, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. *Pharmacol Res* 2015;101:74-85.
131. Sacker A, Done D, Crow T. Obstetric complications in children born to parents with schizophrenia: a

meta-analysis of case-control studies. *Psychol Med* 1996;26:279-287.

132. Sadowski A, Todorow M, Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. *BMJ Open* 2013;3:e003062.
133. Sakai T, Ohtsu F, Mori C, Tanabe K, Goto N. Signal of miscarriage with aripiprazole: adisproportionality analysis of the Japanese Adverse Drug Event Report Database. *Drug Saf* 2017;40(11):1141-1146.
134. Scalzo F, Ali S, Holson R. Behavioral effects of prenatal haloperidol exposure. *Pharmacol Biochem Behav* 1989;34(4):727-31.
135. Schneid-Kofman N, Sheiner E, Levy A. Psychiatric illness and adverse pregnancy outcome. *Int J Gynaecol Obstet* 2008;101:53-56.
136. Sebire N, Jolly M, Harris J, Wadsworth J, Joffe M, Beard R, Regan L, Robinson S. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. *Int J Obesity Related Metabolic Disord* 2001;25:1175-82.
137. Seeman M. Secondary effects of antipsychotics: women at greater risk than men. *Schizophr Bull* 2009;35(5):937-948.
138. Shao P, Ou J, Peng M, Zhao J, Chen J, Wu R. Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis *Plos ONE* 2015;10(4):e0123373.
139. Shaw G, Velie E, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. *JAMA* 1996;275(14):1093-1096.
140. Skovlund C, Mørch L, Kessing L, Lidegaard O. Association of hormonal contraception with depression. *JAMA Psychiatry* 2016;73(11):1154-1162.
141. Slone D, Siskind V, Heinonen O, Monson R, Kaufman D, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. *Am J Obstet Gynecol* 1977;128(5): 486-8.
142. Stein A, Pearson R, Goodman S, Rapa E, Rahman A, McCallum M, Howard L, Pariante C. Effects of perinatal mental disorders on the fetus and child. *Lancet* 2014;384(9956):1800-1819.
143. Štika L, Elisová K, Honzáková H, Hrochova H, Plechatoa H, Strnadova J, Skop B, Svihovec J, Vachova M, Vinar O. Effects of drug administration in pregnancy on children's school behaviour. *Pharmaceutisch Weekblad. Scientific Edition* 1990;12(6):252-255.
144. Stoner S, Sommi R, Marken P, Anya I, Vaughn J. Clozapine use in two full-term pregnancies. *J Clin Psychiatry* 1997;58(8):364-365.
145. Sutter-Dallay A, Bales M, Pambrun E, Glangeaud-Freudenthal N, Wisner K, Verdoux H. Impact of prenatal exposure to psychotropic drugs on neonatal outcome in infants of mothers with serious

psychiatric illnesses. *J Clin Psychiatry* 2015;76(7):967-73.

146. Svensson A, Lichtenstein P, Sandin S, Hultman C. Fertility of first-degree relatives of patients with schizophrenia: a three-generation perspective. *Schizophr Res* 2007;91:238-245.
147. Taylor C, Stewart R, Ogden J, Broadbent M, Pasupathy D, Howard L. The characteristics and health needs of pregnant women with schizophrenia compared with bipolar disorder and affective psychoses. *Br Med Council Psychiatry* 2015;15:88.
148. Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis. *J Clin Psychopharmacol* 2015;35(5):559-565.
149. The Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines https://www.ranzcp.org/Files/Resources/Publications/CPG/Clinician/CPG_Clinician_Full_Schizophrenia-pdf.aspx Also published in *Aust N Z J Psychiatry* 2016;50(5):1-117.
150. Toh S, Li Q, Cheetham T, Cooper W, Davis R, Dublin S, Hammad T, Li D, Pawloski P, Pinheiro S, Raebel M, Scott P, Smith D, Bobo W, Lawrence J, Dashevsky I, Haffenreffer K, Avalos L, Andrade S. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US 2001-2007: a population-based study of 585,615 deliveries. *Arch Womens Ment Health* 2013;16(2):149-157.
151. Trixler M, Gati A, Fekete S, Tenyi T. Use of antipsychotics in the management of schizophrenia during pregnancy. *Drugs* 2005;65(9):1193-206.
152. Vavrusova L, Konikova M. Clozapine administration during pregnancy. *Ceska Slovenska Psychiatrie* 1998;94:282-285.
153. Vemuri M, Rasgon N. A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain. *J Clin Psychiatry* 2007;68(12):1989.
154. Vigod S, Seeman M, Ray J, Anderson G, Dennis C, Grigoriadis S, Gruneir A, Kurdyak P, Rochon P. Temporal trends in general and age-specific fertility rates among women with schizophrenia (1996-2009): a population-based study in Ontario, Canada. *Schizophr Res* 2012;139(1-3):169-175.
155. Vigod S, Kurdyak P, Dennis C, Gruneir A, Newman A, Seeman M, Rochon P, Anderson G, Grigoriadis S, Ray J. Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. *Br J Obst Gynaecol* 2014;121(5):566-74.
156. Vigod S, Gomes T, Wilton A, Taylor V, Ray J. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. *BMJ* 2015;350:h2298.
157. Viguera A, Cohen L, Baldessarini R, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. *Can J Psychiatry* 2002;47(5):426-436.

158. Viguera A, Whitfield T, Baldessarini R, Newport D, Stowe Z, Reminick A, Zurick A, Cohen L. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. *Am J Psychiatry* 2007;164(12):1817-1824.
159. Waldman M, Safferman A. Pregnancy and clozapine. *Am J Psychiatry* 1993;150(1):168-9.
160. Walker A, Rosemberg M, Balaban-Gil K. Neurodevelopmental and neurobehavioral sequelae of selected substances of abuse and psychiatric medications in utero. *Child Adolesc Psychiatric Clin North Am* 1999;8(4):845-867.
161. Waller D, Shaw G, Rasmussen A, Hobbs C, Canfield M, Siega-Riz A, Gallaway M, Correa A. Pre-pregnancy obesity as a risk factor for structural birth defects. *Arch Pediatrics Adolesc Med* 2007;161:745-750.
162. Wangel A, Molin J, Moghaddassi M, Ostman M. Prior psychiatric inpatient care and risk of caesarean sections: a registry study. *J Psychosom Obstet Gynaecol* 2011;32(4):189-197.
163. Webb R, Abel K, Pickles A, Appleby L. Mortality in offspring of parents with psychotic disorders: a critical review and meta-analysis. *Am J Psychiatry* 2005;162(6):1045-56.
164. Webb R, Pickles A, King-Hele S, Appleby L, Mortensen P, Abel K. Parental mental illness and fatal birth defects in a national birth cohort. *Psychol Med* 2008;38(10):1495-503.
165. Werler MM, Louik C, Shapiro S, Mitchell A. Pre-pregnancy weight in relation to risk of neural tube defects. *JAMA* 1996;275(14):1089-1092.
166. Wesseloo R, Kamperman A, Munk-Olsen T, Pop V, Kushner S, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. *Am J Psychiatry* 2016;173:117-127.
167. Westin A, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Treatment with antipsychotics in pregnancy: changes in drug disposition. *Clin Pharmacol Ther* 2018;103(3):477-484.
168. Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. *Arch Womens Ment Health* 2009;12:53-57.
169. Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences: the Tromso Study, 1986-1995. *Arch Int Med* 2000;160(18):2847-2853.
170. Wisner K, Gracious B, Piontek C, Peindl K, Perel J. Postpartum disorders: phenomenology, treatment approaches, and relationship to infanticide, in *Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill*. Ed. Spinelli MG. Washington DC, American Psychiatric Publishing, 2002, pp 36-60.
171. Worly B, Gur T. The effect of mental illness and psychotropic medication on gametes and fertility: a systematic review. *J Clin Psychiatry* 2015;76(7):974-985.
172. Worsley R, Gilbert H, Gavrilidis E, Naughton B, Kulkarni J. Breastfeeding and psychotropic medication. *Lancet* 2013;381:905.

173. Yeong CC; Worsley R; Gilbert H; Kulkarni J. Gestational diabetes in women with mental illness. *Aust N Z J Psychiatry* 2014;48(10):958.
174. Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. *Am J Psychiatry* 2007;164:11.
175. Yogev Y, Ben-Haroush A, Kaplan B. Maternal clozapine treatment and decreased fetal heart rate variability. *Int J Gynecol Obstet* 2002;79(3):259-260.
176. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case control study. *Lancet* 2000;356:1219-1223.

Contact Us

Please contact Ms Alisa Turbić on 9076 6591 if you have any queries about getting involved in NRAMP research study. Alternatively, you may email Alisa at maprc-nramp@monash.edu with any enquiries.